Disease Landscape and Forecast Insights

Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-ASAs), which are often effective…

Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of ulcerative colitis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the total and diagnosed…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key ulcerative colitis patient populations covering 171 countries and…

Tumor necrosis factor (TNF)-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira, biosimilars of both drugs, where available) are the mainstay of biological treatment for moderate to…

Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α) inhibitors are…

The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz / Xeljanz XR) for moderate to severe…

Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum, characterized by diarrhea, abdominal pain, rectal bleeding, fever, and weight loss. The…